Search
Streptococcus pneumoniae type 1 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10319ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For InjectionStreptococcus pneumoniae type 6b capsular polysaccharide antigen
go.drugbank.com/drugs/DB10324ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For InjectionStreptococcus pneumoniae type 7f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10325ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For InjectionStreptococcus pneumoniae type 9v capsular polysaccharide antigen
go.drugbank.com/drugs/DB10328ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For InjectionStreptococcus pneumoniae type 19f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10336ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For InjectionAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalThe phase II of the same study showed that in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (NSCLC), adagrasib was efficient without new safety signals. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.
Eletriptan
go.drugbank.com/drugs/DB00216ApprovedInvestigationalEletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Cyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalAn anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. … It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Categories: Hormonal Contraceptives for Systemic Use, Contraceptive Agents, MaleProline
go.drugbank.com/drugs/DB00172ApprovedInvestigationalNutraceuticalIt is an essential component of collagen and is important for proper functioning of joints and tendons.
Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSIONBeremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigationalDeveloped by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.
Categories: Preparations for Treatment of Wounds and Ulcers